LIVN - LivaNova PLC Stock Analysis

Stock Taper

OPPORTUNITY RADAR SCREENER COMPARE ANY 2 STOCKS

LIVN

LIVANOVA PLC

NASDAQ

$75.91

▼ DOWN 0.03% (-0.02)

KEY STATISTICS

Market Cap$4.16 B

52w High$85.76

52w Low$48.82

Dividend Yield—

Frequency—

P/E18.03

Volume467.18K

Shares Out.54.93M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Vladimir A. Makatsaria

COMPENSATION 2026

Salary$286,826

Stock Awards$4,746,297

Incentive Plan Pay$0

All Other Comp.$1,552,221

Total$8,210,340

ABOUT

SECTOR

Healthcare

WENT PUBLIC

October 19, 2015

METHOD OF GOING PUBLIC

Reverse Merger

FULL TIME EMPLOYEES

3,300

PRICE TARGET

Target High$105.00

Target Low$85.00

Target Median$92.50

Target Consensus$93.33

UPCOMING EARNINGS

DateNov 4, 2026

DayWednesday

Rev. Est.$381.06M

NOV

WED

ETFS HOLDING THIS STOCK

ETFS HOLDING

221

LISTED HERE

RANKED BY POSITION SIZE

INSTITUTIONAL OWNERSHIP

SHARES OWNED

60.13%

HOLDERS

451

TOP 8 OF 451 · RANKED BY POSITION SIZE

Primecap Management Co/Ca/

4.4M sh

$232.82M

Millennium Management LLC

Hood River Capital Management LLC

2.6M sh

$210.96M

Aqr Capital Management LLC

2.5M sh

$154.38M

Artisan Partners Limited Partnership

2.4M sh

$127.13M

PRICE

$75.91 ▼ DOWN 0.03% (−$0.02)

About LivaNova PLC

https://www.livanova.com ↗

LivaNova PLC is a global medical device company specializing in cardiopulmonary, neuromodulation, and circulatory support solutions for healthcare providers, including implantable devices for epilepsy, depression, and heart failure.

INDUSTRY

Medical - Devices

A PRODUCT LIVANOVA PLC IS KNOWN FOR

Essenz Perfusion System

A next-generation heart-lung machine that provides a patient-tailored approach to cardiopulmonary bypass procedures. Its recent global launches in major markets highlight it as a key product for LivaNova's current growth.

COMPETITORS

COMPETITOR

LivaNova in 2025

SENTIMENT: − NEGATIVE

LEGAL · MARCH 2025

LivaNova Records €333.3 Million Liability Following Italian Supreme Court Ruling on Environmental Damages

In a major legal setback, LivaNova was found jointly liable for environmental damages by the Italian Supreme Court, stemming from a pre-merger entity. The ruling on March 14, 2025, forced the company to record a significant liability of approximately $363 million, raising concerns among investors about the financial impact.

LEADERSHIP STRATEGY · NOVEMBER 2025 · IN PROGRESS

LivaNova Unveils Long-Range Strategic Plan to Enter Obstructive Sleep Apnea Market and Fortify Core Businesses

At its 2025 Investor Day, LivaNova's leadership presented a comprehensive strategic roadmap and long-range financial plan, signaling a major push into the Obstructive Sleep Apnea (OSA) market. This move leverages the company's neuromodulation expertise to enter a new high-growth area, while simultaneously aiming to maximize growth in its core Cardiopulmonary and Epilepsy businesses.